Biogen Cost Of Revenue from 2010 to 2024

BIIB Stock  USD 155.33  2.13  1.35%   
Biogen's Cost Of Revenue is increasing over the years with slightly volatile fluctuation. Overall, Cost Of Revenue is expected to go to about 2.7 B this year. From 2010 to 2024 Biogen Cost Of Revenue quarterly data regression line had arithmetic mean of  1,503,533,733 and r-squared of  0.97. View All Fundamentals
 
Cost Of Revenue  
First Reported
1989-09-30
Previous Quarter
704.8 M
Current Value
638.7 M
Quarterly Volatility
207.8 M
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Biogen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biogen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 257.5 M, Interest Expense of 259.2 M or Selling General Administrative of 2.6 B, as well as many indicators such as Price To Sales Ratio of 3.62, Dividend Yield of 0.0022 or PTB Ratio of 2.4. Biogen financial statements analysis is a perfect complement when working with Biogen Valuation or Volatility modules.
  
Check out the analysis of Biogen Correlation against competitors.

Latest Biogen's Cost Of Revenue Growth Pattern

Below is the plot of the Cost Of Revenue of Biogen Inc over the last few years. Cost of Revenue is found on Biogen Inc income statement and represents the costs associated with goods and services Biogen provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Biogen's Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biogen's overall financial position and show how it may be relating to other accounts over time.
Cost Of Revenue10 Years Trend
Slightly volatile
   Cost Of Revenue   
       Timeline  

Biogen Cost Of Revenue Regression Statistics

Arithmetic Mean1,503,533,733
Geometric Mean977,843,448
Coefficient Of Variation52.17
Mean Deviation634,680,018
Median1,630,000,000
Standard Deviation784,318,726
Sample Variance615155.9T
Range2.7B
R-Value0.98
Mean Square Error20756T
R-Squared0.97
Slope172,609,743
Total Sum of Squares8612182.1T

Biogen Cost Of Revenue History

20242.7 B
20232.5 B
20222.3 B
20212.1 B
20201.8 B
2019B
20181.8 B

About Biogen Financial Statements

Biogen stakeholders use historical fundamental indicators, such as Biogen's Cost Of Revenue, to determine how well the company is positioned to perform in the future. Although Biogen investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biogen's assets and liabilities are reflected in the revenues and expenses on Biogen's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biogen Inc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue2.5 B2.7 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:
Check out the analysis of Biogen Correlation against competitors.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.02)
Earnings Share
10.9
Revenue Per Share
66.122
Quarterly Revenue Growth
(0.03)
Return On Assets
0.0499
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.